Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Other EventsItem 8.01. Other Events
On January22, 2018, Editas Medicine,Inc. (the “Company”) registered for resale 56,099 shares of the Company’s common stock, par value $0.0001 per share, to a prospectus supplement under its automatic shelf registration statement on FormS-3 (File No.333-222266), filed with the Securities and Exchange Commission on December22, 2017 (the “Registration Statement”). The opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP, as to the validity of these shares of common stock, filed as Exhibits 5.1 and 23.1 to this Current Report on Form8-K, respectively, are incorporated by reference into the Registration Statement.
Item 8.01. Financial Statements and Exhibits.
(d)Exhibits
Editas Medicine, Inc. ExhibitEX-5.1 2 a18-3472_2ex5d1.htm EX-5.1 Exhibit 5.1 +1 617 526 6000 (t) +1 617 526 5000 (f) wilmerhale.com January 22,…To view the full exhibit click here
About Editas Medicine,Inc. (NASDAQ:EDIT)
Editas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.